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A B S T R A C T
Artemether (AM) plus azithromycin (AZ) rectal co-formulations were studied to provide pre-referral
treatment for children with severe febrile illnesses in malaria-endemic areas. The target proﬁle required
that such product should be cheap, easy to administer by non-medically qualiﬁed persons, rapidly
effective against both malaria and bacterial infections. Analytical and pharmacotechnical development,
followed by in vitro and in vivo evaluation, were conducted for various AMAZ coformulations. Of the
formulations tested, stability was highest for dry solid forms and bioavailability for hard gelatin capsules;
AM release from AMAZ rectodispersible tablet was suboptimal due to a modiﬁcation of its micro-
crystalline structure.
ã 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
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According to recent WHO (world health organization) data
(WHO, 2012a), 6.9 million of children under the age of ﬁve died in
2011. The risk of dying for a child is highest in the neonatal period,
and about 16.5 times higher for children under ﬁve in sub-Saharan
Africa compared to children in developed regions. WHO estimates
that more than half of these early child deaths are caused by
conditions that could be prevented or treated with existing simple,
affordable interventions.
Pneumonia and malaria together cause the majority of deaths
from infectious diseases, representing respectively 17% and 7% of* Corresponding author at: University of Bordeaux, Faculty of Pharmacy, 146 rue
Leo Saignat, Bordeaux 33076, France. Tel.: +33 557571229/224; fax: +33 557571197.
E-mail addresses: tina.kauss@u-bordeaux.fr, tikauss@yahoo.fr (T. Kauss).
http://dx.doi.org/10.1016/j.ijpharm.2014.04.023
0378-5173/ã 2014 The Authors. Published by Elsevier B.V. This is an open access articdeaths of children under ﬁve. Malaria deaths are caused by
Plasmodium falciparum, and two-thirds of the pneumonia deaths
are caused by Streptococcus pneumoniae; as a result these two
organisms kill almost two million children each year in tropical
countries (WHO, 2012a).
The difﬁculty in distinguishing severe malaria with acidotic
breathing from pneumonia in children has been well documented
(Bergman et al., 2004; Hoban et al., 2001; O’Dempsey et al., 1993,
1994). In general malaria is overdiagnosed and severe bacterial
infections are underdiagnosed. Clinical and pathology studies
point to the diagnostic uncertainty and considerable overlap
between severe malaria and sepsis. In up to 20% of children dying
with an in-hospital diagnosis of cerebral malaria, a different cause
is found at autopsy (Taylor et al., 2004) and both conditions coexist
in 15–20% of cases (Berkley et al., 2005).
Therefore correct diagnosis and treatment cannot be expected
in villages and rural health centres where most cases occur. Thele under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
Table 1
Comparison of pH mobile phases composed by 80% of CH3OH and 20% of phosphate
buffer (30 mM).
w
wpHof buffer
s
wpHmobile
phasea
kAZ kAM Asymmetry of AZ
peak
RsAM/AZ
8.4 10.3 4.48 3.15 1.13 2.27
8.0 10.2 4.34 3.12 1.11 2.76
7.5 10.0 4.21 3.14 1.12 2.49
7.0 9.4 4.01 3.19 1.10 1.67
a Measurement performed at room temperature (i.e. 22 C, air conditioned).
Table 2
S/N ratio of compounds at various wavelengths.
Compound Wavelength (nm)
210 212 215
S/N
DHA 500 mg L1 72 92 100
AM 350 mg L1 28 31 30
AZ 500 mg L1 220 201 172
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in 1992 by UNICEF and WHO, recommend presumptive malaria
treatment for all children with fever higher than 37.5 C in malaria-
endemic areas and that both antibiotics and antimalarial drugs are
given to seriously ill febrile children as pre-referral treatment of
malaria or bacterial sepsis.
To prevent death, treatment must be available near home,
outside hospitals, and as close to the village or household as
possible. Malaria and other febrile illnesses are frequently treated
at home in malaria endemic areas (Dolecek et al., 2008;
Greenwood et al., 2007). When oral treatment is no longer
possible, and where injectable medications cannot be safely
administered, rectal formulations can be administered by unqual-
iﬁed persons like parents or health volunteers. While rectal
artesunate has been shown to be an effective pre-referral
treatment for malaria (Gomes et al., 2009), were both malaria
and pneumonia are prevalent, a combined antibiotic–antimalarial
treatment is necessary. Treating malaria only might delay speciﬁc
treatments of other febrile diseases with similar symptoms, such
as sepsis and pneumonia (Whitty et al., 1999). Currently, systemic
large spectrum antibiotics are available as oral or injectable
formulations – of which none is suitable for pre-referral treatment
in pneumonia and malaria endemic regions. A ﬁxed-dose
antimalarial–antibiotic coformulation would be highly desirable
and practical and was thus investigated.
The minimal characteristics of the target product proﬁle (TPP)
were: (i) active principles: well-known, in-use; physico-chemical
compatibility between active ingredients when co-formulated; (ii)
formulation: uncomplicated, easy to scale-up, inexpensive to
manufacture; well-known, inexpensive excipients; rapidly bio-
available; (iii) product development: simple, rapid, inexpensive;
(iv) stability: suited to tropical conditions; (v) price: low-cost (both
cost-of-goods and ﬁnal product); (vi) efﬁcacy: rapidly acting
antimalarial and broad-spectrum antibiotic (to include main
bacterial species causing sepsis and pneumonia in neonates,
infants, toddlers and children), with as little resistance existing as
possible; (vi) safety: proven general safety proﬁle of active
ingredients. The preliminary, pre-clinical development of such
formulation was described in this article.
2. Material and methods
2.1. Material
Artesunate (AS), AM, AZ and dihydroartemisinin (DHA) were
purchased from Knoll BASF Pharma (Liestal, Switzerland), Sanoﬁ
(France), Pﬁzer (USA) and Sigma–Aldrich (Saint-Quentin Fallavier,
France), respectively. Excipients were of pharmaceutical grade.
Sodium laurylsulfate (SLS), colloïdal silica (Aerosil 300), sodium
croscarmellose, polyvinylpyrrolidone (PVP), talc and magnesium
stearate were pourchased from Cooper (France). Different grades of
PEG (polyethylenglycol) were purchased form Fagron (France).
Microcrystaline cellulose (Avicel PH302) was purchased from FMC
Biopolymer (Ireland). Betain and Lutrol were purchased form VWR
(france) and BASF (Germany) respectively. Analytical solvents,
acetonitrile and methanol were isocratic HPLC grade, purchased
from Prolabo VWR (Leuden, Belgium). KH2PO4 and Na2HPO4, 12H2O
were from Merck (Darmstadt, Germany).
2.2. HPLC analysis and method optimization
2.2.1. HPLC conditions
The liquid chromatography system consisted of a Spectra
System P4000 pump, a UV 6000LP detector with a cell path length
of 50 mm, an AS 3000 autosampler and a SN 4000 system
controller from TSP (Courtaboeuf, France). Column was Luna C8 (2)100 A EC 5 mm, 150  4.6 mm (Phenomenex, France) thermostated
with 560-CIL (Cluzeau Info Labo, Saint Foy la Grande, France). The
ﬂow rate was 1 mL min1. The sample injection volume was 5 mL.
For method optimization, several mobile phases and detection
wavelenghts were screened (Tables 1 and 2).
2.2.2. Solubility study of AM and AZ in presence of lutrol
In a dissolution tester three bowls were ﬁlled with 1 L of
phosphate buffer 15 mM pH 8 to simulate rectal pH conditions.
Accurately weighed amounts of approximately 400 and 300 mg of
AZ and AM were respectively added to each vessel. Lutrol was
added to two of the three vessels at 2% and 5% of tablet mass (1.4 g).
Samples were taken at time zero and at time points of 1 h, 2 h and
4 h. Homogeneity of solutions was tested by sampling each time
point twice.
Determination of active pharmaceutical ingredient (API)
content was obtained by calibration curves of AM and AZ at ﬁve
different concentration levels (10%, 40%, 70%, 100% and 120%) in
presence or absence of lutrol at 5%. Stock solution for each
concentration level of AZ and AM were prepared by dissolving an
accurately weighed amount of each drug and/or excipient in 50 mL
of mobile phase then ﬁltrated in a 0.45 mm ﬁlter. One milliliter of
the ﬁltrated solution of each concentration level was diluted with
phosphate buffer pH 8 up to 20 mL. A 100% standard solution
contained 400 and 300 mg L1 of AZ and AM, respectively. These
values were based on the theoretical tablet drug content. All
calibration curves were proven to be linear. Furthermore, no
difference was observed in presence or in absence of lutrol at 5%.
2.3. Formulations tested
2.3.1. Compatibility study between AZ and AM
Compatibility study between both APIs, namely AZ and AM, was
performed. Binary physical mixture of precisely weighted APIs was
mixed using Turbula (France) at 67 rpm for 10 min. The mixture
was divided into three parts, T0, ambient condition and accelerated
(40 C) condition. Samples were taken up till 3 months and
analyzed using HPLC method as described.
AM and AZ compatibility was further evaluated using
differential scanning calorimetry (DSC). DSC analysis was per-
formed using Mettler Toledo TA controller and DSC30,
(Switzerland) with STARe software. DSC method consisted in a
heating rate of 5 C min1 in the range of 30–180 C. Samples of 6–
8 mg were precisely weighted in aluminium pans, sealed and
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was used as reference.
2.3.2. Compatibility study between APIs and excipients
Excipients chosen were checked for their usage among the ones
already used in commercial formulations with AZ and AM.
Compatibility was considered acquiered for excipients commer-
cially available with both APIs separately. In addition, Am and AZ
compatibility study with lutrol and talc were carried out. Six
samples of AM, AZ or both APIs were added to lutrol or talc
separately, then mixed (Turbula, France) at 67 rpp for 10 min and
kept at 40 C during 3 months. Samples were taken at time zero
and then at 1 month, 2 months and 3 months. AM and AZ at three
different concentrations levels (80%, 100% and 120%) were
prepared in presence and in absence of excipient tested. Stock
solutions for each concentration level of AZ and AM were prepared
by dissolving an accurately weighed amount of each drug and/or
excipient in 50 mL of methanol then ﬁltrated with 0.45 mm nylon
ﬁlters. Five milliliters of the ﬁltrated solution was diluted up to
10 mL with the HPLC mobile phase. A 100% standard solution
contained 500 mg L1 of AZ and AM, each. All calibration curves
were linear. Calibration curves statistically not different in
presence or in absence of lutrol and talc.
2.3.3. Preparation of tested formulations
All tested formulations (Table 3) were prepared in our
laboratory. ASAM gels were prepared either dispersing gelling
excipient in the aqueous solution containing both APIs or
alternatively, by preparing a blank gel and then adding successively
both APIs. Gel liquefaction occurred rapidly in both cases.
PEG suppositories were prepared by dispersing both APIs in the
melted PEG under stirring. Formulation was molded in suppositoryTable 3
Summary of tested formulations for rectal administration of antimalarial–antibiotic co
APIs Formulation Immediate
compatibility
Stability Anim
phar
kine
Artesunate + azithromycin Gel (several
formulations)
No No ND 
PEG suppo-
sitory
PEG 6000
monolayer or
bilayer
No No 
Eudragit1 encapsulated
AS could be
considered
for PEG
inclusion,
however
problems of
formulation
encapsulated
drug capacity
PEG
1500/
4000
Yes Interrupted
(colour
change)
Hard capsule Yes No ND No g
Artemether + azithromycin PEG suppository No ND NDb
Hard capsule With LSa No No 
LSa–AM
interaction
Double
granulation
necessary
Without
LSa
Yes Yes Yes 
Rectodispersible tablet Yes Yes Low AM
absorption
No g
ND = not determined.
a LS = Na laurylsulfate.
b AM suppository in monotherapy gave no absorption.moulds, left at room temperature until solidiﬁcation, and then
leveled before taking them out of the moulds. Suppositories were
stored in a desiccator.
Hard gelatin capsules (HGC) were prepared by ﬁlling the
powder mixture containing both APIs, a ﬁller and a lubricant
(mixed using Turbula at 67 rpm for 10 min) into gelatin capsules
(size 000), using a semiautomatic capsule ﬁller (LGA, QB300,
France).
Rectodispersible tablets were prepared by direct compression
using laboratory scale alternative compressor (Korsch pressen,
type EK0, Berlin, Germany).
2.4. In vitro evaluation of formulations
Common pharmacotechnical tests (uniformity of mass, tablet
hardness and friability, etc) were performed following European
pharmacopoeia 8.0 methods and criteria.
2.4.1. Dissolution assay for AZ and AM cotherapy dosage forms
The apparatus used was paddle Sotax AT 7 (Basel, Switzerland)
at 37 C  0.5 C and 50 rpm. Various media were tested (cf. result
Section 3.3). Finally, a bi-phasic dissolution method, initially
developed for AM tablets (Gabriëls and Plaizier-Vercammen,
2004), was adapted for AMAZ cotherapy. Brieﬂy, 150 mL of
50 mM phosphate buffer pH 6.0 and 100 mL of isooctane were
placed into teach dissolution bowel. Preliminary data showed that
the pH variation between 5.5 and 7.0 did not modify AZ and AM
dissolution proﬁles signiﬁcantly. Phase separation was at the
paddle level, ensuring the agitation of both phases. Each form
(ballasted capsule or tablet, n = 6) was placed at the bowel bottom
(into the aqueous phase). At deﬁned times (0/10/20/30/45/75 min),
samples of 0.5 mL buffer and 0.5 mL isooctane media were takentherapy and conclusions.
al
maco-
tics
State Remarks
No go Gel liquefaction; could propose extemporaneous preparation
type DIASTAT1, but high additional costs
ND Stopped
o AS degradation after 6 weeks at 40C/75% RH
Stoppedb Problems of drug release consecutive to AM-PEG interaction
(shell formation); 0.1% of LSa in dissolution medium or 1% LSa
in suppository are necessary for in vitro drug release.
ND No go
Potential
candidate
o Low absorption may be caused by aggregation between AM and
AZ.
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equipped syringes. 300 mL of organic phase was evaporated at
60 C and re-dissolved in 1550 mL of HPLC mobile phase, then
completed with 450 mL of buffer phaseand mixed before injection
in HLPC system.
2.4.2. Preliminary stability study
Preliminary stability study was performed on several formu-
lations: ASAZ capsules, AMAZ tablets and capsules. Prepared
batches of each formulation were divided into T0 condition,
ambient condition and accelerated aging condition (40 C, 75% RH)
using in a climatic chamber (Froilabo/Frilabo, France). All forms
were placed into Bakelite stoppered glass vials containing each 30
dosage forms (5 vials per condition). At deﬁned time (0/1/2/3/6
months for capsules and 0/1/2/3 months for tablets), vials were
taken for aspect, content and drug release analysis (0 and 6
months). For AM and AZ content determination, crushed tablets
(n = 6) or capsule content (n = 10) was dissolved directly in HPLC
mobile phase, then analyzed using HPLC method described.
2.5. In vivo bioavailability evaluation
2.5.1. Animal experiments
Animal experiments were performed at Etablissement Français
du Sang (EFS, Aquitaine-Limousin, Bordeaux, France; accreditation
number for animal experimentation nA33063080).
Five adult healthy New-Zealand white rabbits, provided by « Le
grand Claud », (Eyvirat, Dordogne, France), were used for the
pharmacokinetic study of each form. Animals were housed in
individual cages in controlled temperature (18–21 C) and humidi-
ty (40–70%) room. There were fastened for 24 h prior and during
the experimentation but allowed free access to water and glucose
solution (5%).
The administration of each pharmaceutical formulation was
adapted individually to the rabbit body weight at 20 mg/kg of AM
and AZ. AM and AZ (monotherapy) in miglyol were used as rectal
control formulations.
The protocol complied with the European Community guide-
lines (EU directive 2010/63/EU for animal experiments) as
accepted principles for the use of experimental animals and
internal ethic principles.
Blood samples from peripheral ear vessels (at least 1 mL of
blood per time point) were collected into heparinized plastic tubes
by inserting a 22 GA I.V. catheters (BD Insyte1, Spain). They were
collected before administration, then 12 samples in 48 h post-
administration. Blood samples were kept on ice before centrifuga-
tion at 1200 g during 10 min within 30 min after collection. Only
supernatants (at least 500 mL) were transferred into cryo tube and
conserved at 80 C prior analysis.
2.5.2. PK sample analysis
Samples were analyzed using previously described methods for
AM and AZ (Kauss et al., 2012; Tarning et al., 2012).
2.5.3. PK data processing
The maximal concentration (Cmax), and the time to reach the
maximal concentration (Tmax) of each formulation were taken
directly from mean plasma concentration–time proﬁle curves,
whereas the area under the concentration–time curve (AUC) was
calculated using trapezoidal rule. Standard deviations are given for
all PK parameters. Relative bioavailability was estimated from
mean AUC0–48 h. Data at 24 h were analyzed by comparison with
previously obtained parameters (Kauss et al., 2012).2.6. Powder X-ray diffraction
Crystallinity and phase identiﬁcation were obtained by powder
X-ray diffraction analysis (PXRD) performed on a D5005 Bruker/
Siemens diffractometer using the theta/theta geometry with
copper radiation. Samples were deposited on a stainless steel
holder without grinding to avoid artiﬁcial compression effects.
Data were collected for 2u angle range of 3–40 with a step size of
0.02 at a scanning speed 0.06/min. Mixture samples were then
grinded in order to compare the grinding effect with the
compression in tablets products.
2.7. Statistical analysis
Data were analyzed using Student bilateral paired T test. The
difference of p < 0.05 was considered signiﬁcant.
3. Results and discussion
3.1. TPP and the choice of APIs
Considering the abovementioned TPP, only drugs already
registered and in-use were taken into account.
For malaria, artemisinin derivatives are the most potent and
rapidly acting antimalarial drugs available; they are very safe and
well tolerated, and there is no signiﬁcant resistance yet outside
areas of SE Asia (WHO, 2012b). They are the WHO-recommended
ﬁrst-line treatment of uncomplicated malaria as artemisinin based
combination treatment, (ACTs), severe malaria and pre-referral
treatment (WHO, 2010). Based on generally available information
and signiﬁcant experience accumulated in our laboratory on
physico-chemical properties and stability of artemisinin deriva-
tives, the choice was between AM and AS; AM was expected to
have stability advantages, against the considerable experience and
track record existing already on AS.
Furthermore, protecting the artemisinin derivatives against
resistance when deployed is also a major concern, and ideally the
companion antibiotic should also have antimalarial properties.
These principles informed the choice of the antibiotic. Ceftriaxone
(CFX) would be the lead candidate based on antibacterial
characteristics, but has minimal pharmaceutical information
(which meant a longer pharmaceutical development time), had
a relatively high cost-of-goods, and importantly no antimalarial
activity. Of the other two contenders initially considered,
chloramphenicol was dropped for clinical (real and perceived
safety issues; spectrum; resistance) and compatibility reasons
(incompatible with AS in preliminary studies). Eventually, AZ was
selected for further investigation as the antibiotic partner in the
ﬁxed-dose antimalarial–antibiotic combination, for its expanded
antimicrobial spectrum, covering most bacteria responsible for the
main causes of children mortality and including malaria’s parasite
Plasmodium falciparum, for its improved pharmacokinetic charac-
teristics over older macrolides, (Andersen et al., 1995; Dunn and
Barradell,1996; Langtry and Balfour, 1998; Noedl et al., 2007, 2001;
Yeo and Rieckmann, 1995) and for the considerable experience
gained on AZ rectal forms (Kauss et al., 2013, 2012).
3.2. Analytical control method development
3.2.1. Combined dosage of AS and AZ
Several methods were previously developed to test various
combined ASAZ formulations. Some of them were published, like
gel investigation (Gaudin et al., 2008) and HGC investigation
(Boyer et al., 2012) using HPLC/diode array detector (DAD), HPLC/
evaporative light scattering detection (ELSD) or near infrared
spectroscopy. For PEG suppository and Eudragit1 encapsulation
Table 4
Final formulations for of AMAZ capsules and tablets.
API/excipient (% w/w) AMAZ HGC AMAZ tablet
Azithromycin 2H2O
(anhydrous)
51.05
(48.74)
29.13
(27.79)
Artemether 36.56 20.87
Microcrystalline cellulose 12.19 41.3
Croscarmellose sodium – 4.0
Lutrol F68 – 2.0
Colloidal silica 0.20 0.2
Talc – 2.0
Mg stearate – 0.5
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for control quality.
3.2.2. Combined dosage of AM and AZ
As part of previous work, a method had been developed for the
simultaneous content determination of AZ and AM in a supposi-
tory (Gaudin et al., 2011). Beside AM and AZ, DHA, the active
metabolite and main degradation product of artemisinin deriva-
tives, needed to be dosed. Its presence was expected in low
concentrations; therefore the sensitivity of its detection was
studied.
Mobile phase was optimized in order to improve the column
life-span. The column was a grafted silica resistant to basic pH, a
Luna C8(2) which was stable in the range of swpH
w from 1 to 10.
Decreasing wwpH
w from 8.4 to 7.0 at 25 C led to a decrease of
apparent pH of the mobile phase, AZ retention and AM–AZ
resolution whereas AZ peak asymmetry was not signiﬁcantly
different (Table 1). In order to keep sufﬁcient resolution between
AZ and AM a value of wwpH
w equal to 7.5 was selected. The column
was then thermostated at 20 C in order to improve method
robustness. In this condition, DHA was eluted as a unique peak,
improving its sensitivity, with a retention factor equal to 1.37.
Table 2 shows the signal-to-noise (S/N) ratio for AM, AZ and DHA
obtained at various wavelengths. S/N ratio of AM was almost
constant while it decreased from 210 to 215 nm for AZ. DHA S/N
ratio varied in the opposite direction, with a maximum at 215 nm.
Therefore, 215 nm was selected as the optimal wavelength for the
simultaneous detection of AM, AZ and DHA.
The lower limit of quantiﬁcation (LOQ) for AM, AZ and DHA
were 25, 25 and 50 mg L1, respectively.
Method validation was then performed for rectodispersible and
HGC formulations and was used for the solubility, compatibility
and stability studies.
3.3. Preformulation of antimalarial–antibiotic cotherapy
Artemisinin derivatives, AS or AM, were tested for their
compatibility with AZ in a dry powder mixture at 40 C and were
found compatible (HPLC analysis, DSC) after 6 months. All
excipients were either already commercialized in AZ and AM or
AS formulation and therefore considered as compatible, or tested
for their compatibility in physical mixtures to support their choice
for coformulations. As the stress degradation study of the
analytical method validation, performed on APIs, had showed
that AZ and AM are unstable in acidic conditions, excipients with
acidic functions were discarded. The formulations retained
following preliminary explorations are summarized in Table 3.
Their compatibility/feasibility, preliminary stability at 40 C/75%
RH and, for selected ones, bioavailability were evaluated.
An important point of in vitro evaluation was in vitro drug
release assay. AZ aqueous solubility (39 g L1 at pH 7.4 and 37 C
(Pﬁzer, 2013)) was not limiting regarding the dose considered
(421 mg AZ dihydrate). In contrast, artemisinin derivatives are
characterized by their low aqueous solubility: 0.296 g L1 (Kauss
et al., 2010) and 0.161 g L1 (Gabriëls & Plaizier-Vercammen, 2004)
for AS and AM respectively at 37 C. For dosage forms containing
300 mg of an artemisinin derivative, this solubility was insufﬁcient
to meet solubility (ideally sink, i.e. 3.0 g L1, but minimally
0.90 g L1) conditions of the dissolution assay. The dissolution
test was developed targeting AM, since it has lower aqueous
solubility than AS. Varying the buffer pH (5.5–7.5) did not result in
a satisfactory increase in AM solubility. The addition of 1% w/v of
SLS to the buffer at pH 7 was necessary to obtain requested AM
solubility, but this changed the dissolution rate (drug release was
slower for both AM and AZ) as a consequence of the increased
viscosity of the medium. The Gabriëls and Plaizier-Vercammen(2004) octanol–buffer biphasic system was adopted as the best
compromise between physiological conditions and pharmacopoe-
ia speciﬁcations. Of note, as this method required that each sample
was treated individually, the variance of results was inherently
higher than in a conventional monophasic dissolution assay.
The solubility of each API in the other phase i.e. AM in the buffer
phase and AZ in the isooctane phase was showed to be low
(respectively 1.1 0.2% and 1.4  0.1% of considered dose). Both
phases were treated separately but reconstituted in a single sample
before analysis, to give the total amount of both drugs.
3.4. Formulation and in vitro characterization of antimalarial–
antibiotic coformulation
Several pharmaceutical forms were considered: classical
suppository form, dry forms like capsules and tablets and semi-
solid forms, like rectal gels. We have already successfully
developed an AZ rectal formulation (Kauss et al., 2013, 2012).
The additional challenge for developing a coformulation consisted
in obtaining simultaneously good stability and bioavailability of
APIs (AZ and AS or AM) with different physicochemical proﬁles.
ASAZ and AMAZ feasibility studies (Table 3) showed lack of AS
stability. ASAZ gels suffered from liquefaction as soon as both APIs
were included. ASAZ PEG suppositories presented a colour change
and the stability study was interrupted. AS was encapsulated in
several Eudragit1 polymers for protection against degradation;
however, the high apparent density of encapsulated AS rendered
its inclusion in suppositories and HGC technically difﬁcult. As the
compatibility of a dry blend was showed, an extemporaneously
reconstituted gel was considered. Such formulation required a
particular device for its reconstitution/administration. A conve-
nient, commercially available device was the one used for
diazepam rectal gel (DIASTAT1 AcuDialTM of Valeant Pharmaceut-
icals North America), but the additional cost of this primary
conditioning did not comply with our TPP. Accordingly, AS based
coformulations were abandoned for stability (gels, suppositories,
HGC) and/or cost (extemporaneously reconstituted formulations)
issues in favour of AM based coformulations.
Dry AMAZ rectal formulations were selected for further
optimization. First, a simple AMAZ dry powder mixture was
considered to be ﬁlled in HGC. Commonly, HGC are used mainly by
oral route, but could be used for rectal route as well. Two aspects
were considered of particular import during optimization: the
solubility of AM to be enhanced by adding surfactants, and the
ﬂowability of the powder mixture to facilitate the industrial scale
up.
Several AMAZ hard capsule formulations were developed using
lactose as ﬁller, with or without SLS, or PVP. Because of HGC
capacity, and in order to achieve appropriate ﬂowability, these
formulations needed to be granulated or double-granulated
(necessary in case of SLS) before ﬁlling in gelatine cores.
Surfactants containing formulations gave erratic, non-reproduc-
ible drug content and drug release results. These results were
Table 5
AM compatibility with surfactants after 3 months at 40 C (HPLC analysis of AM
drug content).
Mean AM content (%) Coefﬁcient of variation
AM + SLS 101.14 10.83
AM + lutrol F68 96.06 5.40
AM + betain 83.86 0.14
AM + PEG 6000 102.61 2.13
60 A. Gaubert et al. / International Journal of Pharmaceutics 468 (2014) 55–63attributed partially to the double-granulation process and to a
possible interaction between AM and SLS. Finally, surfactants were
excluded from HGC formulation and microcrystaline cellulose was
used as ﬂowability-promoting ﬁller in addition to a lubricant.
Among common lubricants, colloidal silica gave the best results
compared to talc and magnesium stearate (see Table 4 for ﬁnal
formulation).
Beside the HGC coformulation, a rectodispersible tablet was
considered. To optimize the bioavailability of both APIs, the
underlying rationale of this approach was to (i) avoid the shell (i.e.
capsule) and consequently its disintegration delay, (ii) ensure a
rapid disintegration in an environment (the rectum) with little
amounts of liquids, and (iii) enhance the solubility and conse-
quently the absorption of AM by adding a surfactant. When
possible, the excipients choice was made among those used in
existing commercial formulations to avoid compatibility and
regulatory issues. The key points of the development were tablets’
characteristics (e.g. hardness, friability . . . ), rapid disintegration
and AM solubility enhancement. For the latter, surfactant
compatibility studies were performed (cf. Table 5). PEG 6000
was excluded due to the suspected interaction of AM with PEG
1500 and 4000 in preliminary suppository formulation studies
(Table 3) preventing efﬁcient drug release. SLS gave highly variable
results and Betain was associated with AM drug content decrease.
Lutrol 68 was selected as surfactant for further studies of
rectodispersible AMAZ tablet and no feasibility problems were
noticed. Its use was validated for the optimized formulation of
AMAZ rectodispersible tablets.
The characteristics of the ﬁnal formulations retained for further
in vitro evaluations are summarized in Table 5.
AMAZ tablets and capsules were evaluated for customary
pharmacotechnical controls (mass and content uniformity, tablet
friability, disintegration, etc.) according to the European Pharma-
copoeia 8.0 requirements. As there is currently no speciﬁc
monograph for rectodispersible tablets, tablet disintegration was
tested following the monographs of dispersible and vaginal tablets.
All the tested parameters complied with pharmacopoeia stand-
ards.
Dissolution assay and preliminary stability studies were also
performed on these formulations, up to 3 or 6 months for tablets
and HGC respectively (Table 6).
The preliminary stability results showed that contrary to
ASAZ formulations (degradation of AS after 6 weeks), AMAZ
formulations were stable for at least 3 months in accelerated
conditions.Table 6
In vitro evaluation of AMAZ formulations (n = 6, mean  SD).
Time (weeks) Storage condition 
Drug content (%) T0 – 
12 ambient 
12 40/75% RH 
26 40/75% RH 
Drug released at 45 min(%) T0 – 
26 40/75% RH 
ND: not determined.The drug release of both APIs from HGC and AZ from tablets
complied with pharmacopoeia speciﬁcation of conventional drug
release, while drug release was low for AM from rectodispersible
tablets – a surprising ﬁnding, given the addition of a super-
disintegrant and a surfactant to the formulation. As the in vitro
biphasic assay was not representative of physiological conditions
regarding rectal mechanical forces, the formulation was tested in
vivo despite in vitro results. Drug release of both API from HGC was
not signiﬁcantly different (p > 0.05, Student test) after 26 weeks of
accelerated stability compared to the initial release.
3.5. In vivo evaluation
AMAZ coformulations were administered rectally to rabbits and
their bioavailability evaluated. AZ suspension and AM solution in
oily vehicles were used as rectal controls. The results are
summarized in Fig. 1A and B for AZ and AM plasma proﬁles
respectively and in Table 7 for pharmacokinetic parameters.
For ethical reasons this preliminary bioavailability study was
limited to groups of ﬁve animals per experimental condition,
which showed marked variability. Further animal studies con-
taining larger groups of animals would be necessary to reduce the
variability for the selected formulation, but this was beyond the
scope of the current preliminary exploratory study.
AMAZ HGC formulation produced satisfactory absorption for AZ
(comparable AUC and relative bioavailability F0) and delayed but
enhanced absorption of AM (relative bioavailability of 146%,
difference not statistically signiﬁcant due to large standard
deviation) compared to rectal single-agent control formulations.
Compared to previously described AZ monotherapies (Kauss et al.,
2013, 2012), HGC parameters were comparable (107% and 105% of
relative bioavailability for AZ HGC in monotherapy and cotherapy
respectively), but AZ HGC absorption was lower than the one
obtained with AZ suppository (232% of relative bioavailability after
24 h) (Kauss et al., 2012). In conclusion, AZAM HGC provided AZ
absorption comparable to the one obtained with rectal oily
suspension, but did not enhance it. AM alone in HGC was also
administered to rabbits in a monotherapy as a rectal dry form
control condition and gave statistically non different results (AUC
187  71 ng  h/mL, p > 0.05) as AM absorbed from cotherapy.
Furthermore, these results demonstrated that an additional API did
not diminish the absorption rate of AM or AZ form HGC.
AMAZ tablet moderately but non-signiﬁcantly enhanced AZ
absorption (relative bioavailability 133%, p > 0.05), but failed to
provide sufﬁcient AM absorption (relative bioavailability 25%,
p  0.05). These results conﬁrmed the ones obtained during in vitro
evaluation. Despite the presence of a disintegrant and a surfactant,
AM was not adequately absorbed in rabbits.
3.6. Further investigations to explain low AM release of AMAZ tablets
Unexpectedly low AM drug release from AMAZ tablets was
further investigated. Possible explanations are that (i) crystalline
modiﬁcation of AM in tablet form diminished its drug release andAMAZ HGC AMAZ tablet
AZ AM AZ AM
100.4  1.3 101.2  1.1 98.7  1.6 97.6  1.1
101.7  1.0 100.0  0.9 101.2  0.8 100.3  2.7
100.8  0.6 99.0  0.2 99.2  1.8 98.3  2.7
97.3  0.8 100.9  1.5 ND ND
88.0  15.0 78.9  11.0 22.6  3.3 88.8  0.8
93.4  3.6 87.1  11.4 ND ND
Fig. 1. AZ (A) and AM (B) rabbit plasma proﬁles of various rectal formulations administered at 20 mg/kg body weight.
Table 7
AZ and AM disposition in the rabbit after administration of individual drugs as
monotherapy as control (AZ or AM in miglyol) or ﬁxed-dose coformulations (n = 5,
mean  SD).
Control AMAZ HGC AMAZ tablet
AM parameters
Cmax (ng/mL) 35  11 56  18 59  38
Tmax (h) 1.4  0.6 3.0  1.2 0.8  0.2
AUC 0–48 h (ng  h/mL) 126  85 185  130 46  19
F0 100 146 25
AZ parameters
Cmax (ng/mL) 191  49 118  35 410  212
Tmax (h) 0.37  0.32 1.25  0.89 0.80  0.19
AUC 0–48 h (ng  h/mL) 858  198 898  469 1141  404
F0 100 105 133
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signiﬁcantly increase AM solubility – at least not enough to
compensate the decrease induced by crystalline modiﬁcation.
3.6.1. X-ray characterization
Powder X-ray diffraction (PXRD) patterns were determined on
powder of AZ, AM, AMAZ mixture and tablets of AZ, AM and AMAZ
mixture. Each PXRD pattern presented the characteristic peaks of
AZ or AM or both depending on the sample, and no spurious extra
peaks.
All PXRD patterns of samples containing AM, except the AMAZ
tablet, showed a strong preferred orientation effect of the AM
phase as shown by the abnormally intense 020 reﬂection of AM
(Fig. 2A), which may be due to strong anisotropy of the shape of the
AM crystallites. It is worth to note that this effect, which decreased
markedly in the compressed mixture of AMAZ tablets, was present
in all other samples, including the compressed AM (Fig. 2B). This
difference, between the PXRD pattern of the compressed mixture
tablets and the others, constituted the sole distinct feature within
the observed patterns.
In order to better understand this effect, a Rietveld reﬁnement
(Rietveld, 1969) was performed on each PXRD pattern. Thereﬁnement performed on the AMAZ mixture samples led to the
same weight proportions of AM and AZ in the powder and the
tablet samples which were estimated at 40(2)% and 60(2)%
respectively – thus in good agreement with the theoretical
proportions of 42% and 58%, respectively. These results allowed
Fig. 2. Powder X-ray diffraction patterns of AM, AZ and AM/AZ mixture of (A) powder samples and (B) compressed tablet samples.
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and any amorphization during the compression.
The Rietveld reﬁnement of pure compounds conﬁrmed the
strong effect of preferred orientations on both powder and tablet
AM samples, while no signiﬁcant orientation effect could be
detected on AZ samples. The preferred orientations effect were of
the same amplitude between AM powder and tablet samples
(March-Dollase parameter 0.6) (Dollase, 1986), but interestingly,
the Rietveld reﬁnement on AMAZ mixture revealed a signiﬁcantly
different behavior: while the preferred orientations effect was still
strong in the powder mixture (March-Dollase parameter 0.5),Fig. 3. Dissolution study in the presence of lutrol for AZ (A) and AM (B).this effect completely disappeared in the tablet mixture (March-
Dollase parameter 1.0). This indicated that the loss of the
preferred orientations was only due to the compression of the
powder mixture. According to the Rietveld results the distinct
behavior of the AMAZ mixture tablets relative to the powder
mixture might be related to the sole preferred orientations effect
and cannot be attributed to changes in the AM and AZ proportions
in the samples. The total loss of the preferred orientations effect
after compression of the mixture might be due to a change of
crystallites morphology, which was possibly due to either the
breaking of the crystallites into smaller pieces or by the
aggregation of crystallites of AM and AZ. In either case the shape
of the new particles became more isotropic, thus reducing the
preferred orientations. Nevertheless, the ﬁrst hypothesis was
contradicted by the absence of this effect in the pure AM tablet
samples and by low absorption of AM tablets on pharmacokinetic
measurements. Thus aggregation was a more likely explanation.
This hypothesis was further supported by ﬁnding in the Rietveld
reﬁnements of a small broadening of the diffraction peaks at high
theta value for the AMAZ mixture tablet sample only, which was
consistent with micro-deformations of the material caused by
aggregation of AM and AZ crystallites. As grinding of the AMAZ
powder mixture did not lead to the suppression of preferred
orientations, this aggregation would occur in tablet samples only,
and might be due to local surface warming during compression.
Taken together, these results demonstrate that compression
had an effect on the crystalline microstructure and could help to
explain the observed differences in AM release between com-
pressed and uncompressed forms.
3.6.2. AM and AZ solubility enhancement in presence of lutrol
To better characterize the lutrol effect as a surfactant in
enhancing the AM and AZ solubility, the latter was studied in the
presence of 2% lutrol, at tablet dosage form quantities (300 and
400 mg for AM and equivalent anhydrous AZ, respectively).
AZ dissolution rate improved with lutrol at 2% (57% vs. 42%
respectively after 1 h, p < 0.05). After 4 h with 2% lutrol, 76% of the
expected concentration was reached while compared to 60%
without lutrol (Fig. 3A). Conversely, 2% lutrol has no effect on AM
solubility or dissolution rate in tested conditions (Fig. 3B). Similar
results were found for the AMAZ tablet. Additional studies
demonstrated that AM dissolution increased with higher concen-
trations (5%) of lutrol (from 25% to 30% for 0% and 5% of lutrol
respectively, p < 0.05). Further studies are needed now on more
efﬁcient surfactants to improve AM solubility and dissolution rate
on order to compensate the decreased drug release induced by
compression.
A. Gaubert et al. / International Journal of Pharmaceutics 468 (2014) 55–63 634. Conclusions
Our study demonstrates that dry pharmaceutical forms are the
most suited coformulation for an antimalarial–antibiotic combi-
nation treatment in malaria-endemic areas. They provide an easy
to administer, inexpensive, stable formulation, with enhanced AM
rectal bioavailability and comparable AZ bioavailability with
respect to individual rectal preparations. The co-administration
of individually-formulated antimalarial and azithromycin (e.g. AS
rectal soft capsule Rectocap1 and the previously developed AZ
suppository (Kauss et al., 2013)) remains a valid, shorter-term
alternative.
Rectodispersible AMAZ tablets gave satisfactory AZ but low AM
drug release and bioavailability, possibly due to compression-
induced changes in AM crystalline micro-structure.
Acknowledgements
The authors wish to thank the members of Laboratoire de
Technologie Industrielle de Bordeaux, University of Bordeaux, Drs
Pascale Gueroult, Gilles Lemagnen and Mr Denis Larrouture and
M2 students Marine Brepson, François Fagour and Sarah Noury, for
their help for rectodispersible tablets development; and Dr Zoran
Ivanovic, Scientiﬁc director of EFS Aquitaine Limousin, France, for
his help regarding animal experimentation.
This work was supported in part by the Wellcome Trust
foundation, Wellcome Trust Feasibility Award ref: 085242/Z/08/Z.
P. Olliaro is a staff member of the WHO; the authors alone are
responsible for the views expressed in this publication and they do
not necessarily represent the decisions, policy or views of the WHO.
References
Andersen, S.L., Ager, A., McGreevy, P., Schuster, B.G., Wesche, D., Kuschner, R., Ohrt,
C., Ellis, W., Rossan, R., Berrman, J., 1995. Activity of azithromycin as a blood
schizonticide against rodent and human plasmodia in vivo. American Journal of
Tropical Medicine and Hygiene 52, 159–161.
Bergman, M., Huikko, S., Pihlajamaki, M., Laippala, P., Palva, E., Huovinen, P., Seppälä,
H., 2004. Finnish study group for antimicrobial resistance (FiRe Network). Effect
of macrolide consumption on erythromycin resistance in Streptococcus pyogenes
in Finland in 1997–2001. Clinical Infectious Diseases 38, 1251–1256.
Berkley, J.A., Lowe, B.S., Mwangi, I., Williams, T., Bauni, E., Mwarumba, S., Ngetsa, C.,
Slack, M.P., Njenga, S., Hart, C.A., Maitland, K., English, M., Marsh, K., Scott, J.A.,
2005. Bacteremia among children admitted to a rural hospital in Kenya. New
England Journal of Medicine 352, 39–47.
Boyer, C., Gaudin, K., Kauss, T., Gaubert, A., Boudis, A., Verschelden, J., Franc, M.,
Roussille, J., Boucher, J., Olliaro, P., White, N.J., Millet, P., Dubost, J.-P., 2012.
Development of NIRS method for quality control of drug combination
artesunate – azithromycin for the treatment of severe malaria. Journal of
Pharmaceutical and Biomedical Analysis 67–68, 10–15.
Dollase, W.A., 1986. Correction of intensities for preferred orientation in powder
diffractometry: application of the March model. Journal of Applied Crystallog-
raphy 19, 267–272.
Dolecek, C., Tran, T.P., Nguyen, N.R., Le, T.P., Ha, V., Phung, Q.T., Doan, C.D., Nguyen, T.
B., Duong, T.L., Luong, B.H., Nguyen, T.B., Nguyen, T.A., Pham, N.D., Mai, N.L.,
Phan, V.B., Vo, A.H., Nguyen, V.M., Tran, T.T., Tran, T.C., Schultsz, C., Dunstan, S.J.,
K, Stepniewska, Campbell, J.I., To, S.D., Basnyat, B., Nguyen, V.V., Nguyen, V.S.,
Nguyen, T.C., Tran, T.H., Farrar, J., 2008. A multi-center randomised controlled
trial of gatiﬂoxacin versus azithromycin for the treatment of uncomplicated
typhoid fever in children and adults in Vietnam. Public Library of Sciences 3,
e2188.
Dunn, C., Barradell, L.B., 1996. Azithromycin – a review of its pharmacological
properties and use as a 3-day therapy in respiratory tract infections. Drugs 51,
483–505.
Gabriëls, M., Plaizier-Vercammen, J., 2004. Design of a dissolution system for the
evaluation of the release rate characteristics of artemether and dihydroarte-
misinin from tablets. International Journal of Pharmaceutics 274, 245–260.Gaudin, K., Kauss, T., Gaubert, A., Viaud, V., Olliaro, P., White, N.J., 2011. Simultaneous
determination of artemether and azithromycin in suppository by reversed
phase HPLC. Analytical Letters 44, 2732–2743.
Gaudin, K., Barbaud, A., Boyer, C., Langlois, M.-H., Lagueny, A.-M., Dubost, J.-P.,
Millet, P., Fawaz, F., 2008. In vitro release and stability of an artesunate rectal gel
suitable for pediatric use. International Journal of Pharmaceutics 353, 1–7.
Greenwood, D., Finch, R., Davey, P., Wilcox, M., 2007. Antimicrobial Chemotherapy,
ﬁfth ed. Oxford University Press, Oxford.
Gomes, M.F., Faiz, M.A., Gyapong, J.O., Warsame, M., Agbenyega, T., Babiker, A.,
Baiden, F., Yunus, E.B., Binka, F., Clerk, C., Folb, P., Hassan, R., Hossain, M.A.,
Kimbute, O., Kitua, A., Krishna, S., Makasi, C., Mensah, N., Mrango, Z., Olliaro, P.,
Peto, R., Peto, T.J., Rahman, M.R., Ribeiro, I., Samad, R., White, N.J., 2009. Study 13
research group. Pre-referral rectal artesunate to prevent death and disability in
severe malaria: a placebo-controlled trial. Lancet 373, 557–566.
Hoban, D.J., Doern, G.V., Fluit, A.C., Roussel-Delvallez, M., Jones, R.N., 2001.
Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae,
Haemophilus inﬂuenzae, and Moraxella catarrhalis in the sentry antimicrobial
surveillance program, 1997–1999. Clinical Infectious Diseases 32, S81–S93.
Langtry, H.D., Balfour, J.A., 1998. Azithromycin: a review of its use in paediatric
infectious diseases. Drugs 56, 273–297.
Kauss, T., Gaubert, A., Ba, B., Boyer, C., Fawaz, F., Lembege, M., Boiron, J.M., Lafarge, X.,
Lindegard, N., White, N.J., Olliaro, P.L., Millet, P., Gaudin, K., 2013. Pharmaceutical
development and optimization of azithromycin suppository for paediatric use.
International Journal of Pharmaceutics 441, 218–226.
Kauss, T., Gaudin, K., Gaubert, A., Ba, B., Tagliaferri, S., Fawaz, F., Fabre, J.L., Boiron, J.
M., Lafarge, X., White, N.J., Olliaro, P.L., Millet, P., 2012. Development of rectal
forms of azithromycin as an alternative to oral and intra venous administration
for paediatric treatment. International Journal of Pharmaceutics 436, 624–630.
Kauss, T., Fawaz, F., Guyot, M., Lagueny, A.M., Dos Santos, I., Bonini, F., Olliaro, P.,
Millet, P., 2010. Fixed artesunate – amodiaquine combined pre-formulation
study for the treatment of malaria. International Journal of Pharmaceutics 395,
198–204.
Noedl, H., Krudsood, S., Leowattana, W., Tangpukdee, N., Thanachartwet, W.,
Looareesuwan, S., Miller, R.S., Fukuda, M., Jongsakul, K., Yingyuen, K.,
Sriwichhai, S., Ohrt, C., Knirsch, C., 2007. In vitro antimalarial activity of
azithromycin, artesunate and quinine in combination and correlation with
clinical outcome. Antimicrobial Agents and Chemotherapy 51, 651–656.
Noedl, H., Wernsdorfer, H., Krudsood, S., Wilairatana, P., Kollaritsch, H., Wieder-
mann, G., Looareesuwan, S., 2001. Antimalarial activity of azithromycin,
artemisinin and dihydroartemisinin in fresh isolates of Plasmodium falciparum
in Thailand. Acta Tropica 80, 39–44.
O’Dempsey, T.J., McArdle, T.F., Laurence, B.E., Lamont, A.C., Todd, J.E., Greenwood, B.
M., 1993. Overlap in the clinical features of pneumonia and malaria in African
children. Transactions of the Royal Society of Tropical Medicine and Hygiene 87,
662–665.
O’Dempsey, T.J., McArdle, T.F., Lloyd-Evans, N., Laurence, B.E., Baldeh, I., Secka, O.,
Greenwood, B.M., 1994. Importance of enteric bacteria as a cause of pneumonia,
meningitis and septicemia among children in a rural community in The Gambia,
West Africa. Pediatric Infectious Disease Journal 13, 122–128.
Pﬁzer, 2013. Pﬁzer’s Zithromax1 (Azithromycin) physician prescribing information,
revised February 2013. Retrieved from http://labeling.pﬁzer.com/ShowLabel-
ing.spx?id=511 (accessed in August 2013).
Rietveld, H.M., 1969. A proﬁle reﬁnement method for nuclear and magnetic
structures. Journal of Applied Crystallography 2, 65–71.
Taylor, T.E., Fu, W.J., Carr, R.A., Whitten, R.O., Mueller, J.S., Fosiko, N.G., Lewallen, S.,
Liomba, N.G., Molyneux, M.E., 2004. Differentiating the pathologies of cerebral
malaria by postmortem parasite counts. Nature Medicine 10, 143–145.
Tarning, J., Kloprogge, F., Piola, P., Dhorda, M., Muwanga, S., Turyakira, E.,
Nuengchamnong, N., Nosten, F., Day, N.P., White, N.J., Guerin, P.J., Lindegardh,
N., 2012. Population pharmacokinetics of artemether and dihydroartemisinin in
pregnant women with uncomplicated plasmodium falciparum malaria in
Uganda. Malaria Journal 11, 293.
Whitty, C.J., Glasgow, K.W., Sadiq, S.T., Mabey, D.C., Bailey, R., 1999. Impact of
community-based mass treatment for trachoma with oral azithromycin on
general morbidity in Gambian children. Pediatric Infectious Disease Journal 18,
955–958.
WHO, 2010. Guidelines for the Treatment of Malaria, 2nd edition, World Health
Organization. Retrieved from: http://whqlibdoc.who.int/publications/2010/
9789241547925_eng.,df (accessed in August 2013).
WHO, 2012, WHO fact sheet N 178, September 2012: available on http://www.who.
int/mediacentre/factsheets/fs178/en/ (accessed in July 2013).
WHO, 2012, Update on artemisinin resistance – April 2012, available on http://
www.who.int/malaria/publications/atoz/arupdate042012pdf?ua=1/ (accessed
in January 2014).
Yeo, A.E., Rieckmann, K.H., 1995. Increased antimalarial activity of azithromycin
during prolonged exposure of Plasmodium falciparum in vitro. International
Journal for Parasitology 25, 531–532.
